# Silence Therapeutics - Silence to Participate in Investor Conferences

8/25/2021

RNS Number : 6504J

Silence Therapeutics PLC

25 August 2021

## Silence Therapeutics to Participate in September Investor Conferences

25 August 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will present at two virtual investor conferences in September, details of which can be found below:

**Morgan Stanley 19th Annual Global Healthcare Conference**

Format: Fireside Chat

Date: Friday, September 10th

Time: 11:45am EDT / 4:45pm BST

**H.C. Wainwright 23rd Annual Global Investment Conference**

Format: Company Presentation

Date: Monday, September 13th

Time: On-demand starting at 7:00am EDT / 12:00pm BST

Webcasts of the fireside chat and presentation can be accessed via the Investors section of the Silence website at **www.silence-therapeutics.com**. An archived replay of the webcasts will be available on the Company's website following the conference.

**Enquiries:**

---


**Silence Therapeutics plc** Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
**ir@silence-therapeutics.com**

**Investec Bank plc (Nominated Adviser and Broker)** Tel: +44 (0) 20 7597 5970
Daniel Adams/Gary Clarence

**European PR** Tel: +44 (0) 20 3709 5700
**Consilium Strategic Communications**
Mary-Jane Elliott/ Angela Gray / Chris Welsh
**silencetherapeutics@consilium-comms.com**


**About Silence Therapeutics**

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs

(short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit **https://www.silence-therapeutics.com/**.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact **rns@lseg.com** or visit **www.rns.com**.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our **Privacy Policy**.

END

MSCBUGDIBBDDGBS